Redeye’s main take-away is that Nanologica adds support (pharma companies) in Drug Development and adds prospects in the preparative (Chromatography) business. The outlook is also improving, and Nanologica has increased its Silica production capacity substantially. Nanologica’s objective is to convert additional pipeline opportunities over the next 6 to 18 months.